Andre C. Schuh

17.2k total citations · 4 hit papers
181 papers, 7.8k citations indexed

About

Andre C. Schuh is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Andre C. Schuh has authored 181 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Hematology, 54 papers in Genetics and 54 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Andre C. Schuh's work include Acute Myeloid Leukemia Research (114 papers), Chronic Myeloid Leukemia Treatments (53 papers) and Acute Lymphoblastic Leukemia research (53 papers). Andre C. Schuh is often cited by papers focused on Acute Myeloid Leukemia Research (114 papers), Chronic Myeloid Leukemia Treatments (53 papers) and Acute Lymphoblastic Leukemia research (53 papers). Andre C. Schuh collaborates with scholars based in Canada, United States and Germany. Andre C. Schuh's co-authors include Fouad Shalaby, Janet Rossant, Martin L. Breitman, Xiang‐Fu Wu, Terry P. Yamaguchi, Marina Gertsenstein, Mark D. Minden, Vikas Gupta, Joseph Brandwein and Aaron D. Schimmer and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Andre C. Schuh

169 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1995 3.1k citations Andre C. Schuh et al. profile →
A Requirement for Flk1 in Primitive and Definitive Hematopoiesis and Vasculogenesis

1997 726 citations Andre C. Schuh et al. profile →
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Pau Montesinos, Christian Récher et al. profile →
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 47 citations Hartmut Döhner, Keith W. Pratz et al. profile →

Peers

Countries citing papers authored by Andre C. Schuh

Since Specialization

Citations

This map shows the geographic impact of Andre C. Schuh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andre C. Schuh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andre C. Schuh more than expected).

Fields of papers citing papers by Andre C. Schuh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andre C. Schuh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andre C. Schuh. The network helps show where Andre C. Schuh may publish in the future.

Co-authorship network of co-authors of Andre C. Schuh

This figure shows the co-authorship network connecting the top 25 collaborators of Andre C. Schuh. A scholar is included among the top collaborators of Andre C. Schuh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andre C. Schuh. Andre C. Schuh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diagnostic Accuracy in Detecting Fungal Infection with Ultra-Low-Dose Computed Tomography (ULD-CT) Using Filtered Back Projection (FBP) Technique in Immunocompromised Patients 2024 ·Journal of Clinical Medicine ·Luigia D’Errico, (unknown), Mini Pakkal, Micheal McInnis, (unknown), Andre C. Schuh, John Kuruvilla, Mark D. Minden, Narinder Paul	0
2	Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation 2024 ·Annals of Hematology ·Josephine Anne Lucero, (unknown), Igor Novitzky‐Basso, José‐Mario Capo‐Chichi, Tracy Stockley, Vikas Gupta, (unknown), Steven M. Chan, Andre C. Schuh, Mark D. Minden, Jonas Mattsson, Rajat Kumar, Hassan Sibai, Anne Tierens, Dennis Dong Hwan Kim	3
3	Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia 2023 ·Acta Haematologica ·(unknown), Eshetu G. Atenafu, Steven M. Chan, Vikas Gupta, Dawn Maze, Andre C. Schuh, Hassan Sibai, Karen Yee, (unknown)	1
4	P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL 2023 ·HemaSphere ·Daniel L. Menezes, Andrew H. Wei, Hartmut Döhner, Gail J. Roboz, Maria Teresa Voso, Andre C. Schuh, Wendy L. See, (unknown), Arnaud Amzallag, Alberto Risueño, (unknown), Rajasekhar N.V.S. Suragani, Barry Skikne, C.L. Beach, Thomas Prébet, Anita K. Gandhi	1
5	P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE 2023 ·HemaSphere ·Hartmut Döhner, Pau Montesinos, (unknown), Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Jianan Hui, Diego A. Gianolio, Prapti A. Patel, Christian Récher, Stéphane de Botton	0
6	Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis 2023 ·Value in Health ·Xue Li, Hae Sun Suh, Jean Lachaîne, Andre C. Schuh, Keith W. Pratz, Keith A. Betts, Jinlin Song, (unknown), Cat N. Bui	2
7	Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Eshetu G. Atenafu, Taylor Young, Steven M. Chan, Vikas Gupta, Dawn Maze, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai	2
8	Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine 2022 ·Clinical Cancer Research ·Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Récher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo	75
9	CLONAL HEMATOPOIESIS ASSOCIATED MUTATIONS, CARDIOVASCULAR EVENTS, AND ALL-CAUSE DEATH AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA 2020 ·Journal of the American College of Cardiology ·Oscar Calvillo‐Argüelles, (unknown), (unknown), Husam Abdel‐Qadir, (unknown), Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Paaladinesh Thavendiranathan	0
10	Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients 2017 ·Clinical Microbiology and Infection ·(unknown), Abhishek Bhaskaran, L.G. Singer, Deepali Kumar, Atul Humar, (unknown), Jeffrey H. Lipton, John Kuruvilla, Andre C. Schuh, Karen Yee, Mark D. Minden, Aaron D. Schimmer, Coleman Rotstein, Shaf Keshavjee, Tony Mazzulli, Shahid Husain	18
11	Azacitidine in adult patients with acute myeloid leukemia 2017 ·Critical Reviews in Oncology/Hematology ·Andre C. Schuh, Hartmut Döhner, Lisa Pleyer, John F. Seymour, Pierre Fenaux, Hervé Dombret	40
12	A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia 2016 ·Investigational New Drugs ·Karen Yee, (unknown), David W. Hedley, Sue Chow, Joseph Brandwein, Andre C. Schuh, Aaron D. Schimmer, Vikas Gupta, (unknown), (unknown), Lisa W. Le, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Mark D. Minden	27
13	A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults 2014 ·Current Oncology ·Matthew D. Seftel, Michael J. Barnett, Stephen Couban, Brian Leber, John M. Storring, (unknown), (unknown), Anna Christofides, Andre C. Schuh	19
14	High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission 2013 ·Leukemia Research ·(unknown), Eshetu G. Atenafu, Andre C. Schuh, Karen Yee, Mark D. Minden, Aaron D. Schimmer, Vikas Gupta, Joseph Brandwein	5
15	A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over 2008 ·Leukemia ·Joseph Brandwein, Brian Leber, Kang Howson‐Jan, Aaron D. Schimmer, Andre C. Schuh, Vikas Gupta, Karen Yee, James R. Wright, Malcolm J. Moore, (unknown), Mark D. Minden, (unknown)	10
16	Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy 2007 ·American Journal of Hematology ·Joseph Brandwein, Vikas Gupta, Andre C. Schuh, Aaron D. Schimmer, Karen Yee, Wei Xu, Hans A. Messner, Jeffrey H. Lipton, Mark D. Minden	21
17	Treatment of elderly patients with acute lymphoblastic leukemia—Evidence for a benefit of imatinib in BCR-ABL positive patients 2005 ·Leukemia Research ·Joseph Brandwein, Vikas Gupta, Richard A. Wells, Andre C. Schuh, Aaron D. Schimmer, Jeffrey H. Lipton, Hans A. Messner, Qilong Yi, Kathy Chun, Suzanne Kamel‐Reid, Mark D. Minden	14
18	Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells 2004 ·Journal of Immunotherapy ·(unknown), Yonghong Shi, (unknown), Jelena Tomić, David Cervi, Liwei He, (unknown), Mark DeBenedette, Andre C. Schuh, Jeremy L. Baryza, Paul A. Wender, Laszlo Radvanyi, David Spaner	19
19	The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison 2003 ·Bone Marrow Transplantation ·Vikas Gupta, (unknown), Joseph Brandwein, Mark D. Minden, Andre C. Schuh, Richard A. Wells, Kathy Chun, Suzanne Kamel‐Reid, Richard Tsang, Andrew Daly, Thomas Kiss, Jeffrey H. Lipton, Hans A. Messner	33
20	Recombinant urate oxidase (SR 29142) to prevent hyperuricaemia during chemotherapy for haematological malignancies. 1998 ·British Journal of Haematology ·Tim Littlewood, Andre C. Schuh, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact